Table 1. Patient demographics and characteristics at baseline.
| Variable | Total | Previously negative TRUS-guided biopsies | Candidates for active surveillance |
|---|---|---|---|
| No. of patients, n (%) | 155 (100.0) | 58 (37.4) | 97 (62.6) |
| Age at biopsy (y) | |||
| Median (range) | 65.0 (47.0–79.0) | 64.0 (51.0–77.0) | 67.0 (47.0–79.0) |
| Mean±SD | 65.2±7.2 | 63.9±6.5 | 66.0±7.6 |
| PSA (ng/mL) | |||
| Median (range) | 5.74 (0.56–42.76) | 6.47 (1.05–42.76) | 5.55 (0.56–23.47) |
| Mean±SD | 7.63±6.05 | 9.10±8.26 | 6.75±4.01 |
| Prostate volume (cm3) | |||
| Median (range) | 41.0 (12.3–233.0) | 44.6 (17.5–233.0) | 37.9 (12.3–107.4) |
| Mean±SD | 45.7±24.9 | 50.7±32.2 | 42.7±19.0 |
| PSA density (ng/mL/cm3) | |||
| Median (range) | 0.15 (0.04–0.96) | 0.15 (0.04–0.96) | 0.15 (0.04–0.71) |
| Mean±SD | 0.19±0.14 | 0.18±0.14 | 0.19±0.13 |
| Pathologic results in TRUS-guided biopsya, n (%) | |||
| HGPIN | 7 (12.1) | ||
| ASAP | 5 (8.6) | ||
| Benign prostatic tissue | 46 (79.3) | ||
| No. of total cores in TRUS-guided biopsyb | |||
| Median (range) | 12.0 (4.0–15.0) | ||
| Mean±SD | 12.0±1.4 | ||
| No. of positive cores in TRUS-guided biopsyb | |||
| Median (range) | 1.0 (1.0–8.0) | ||
| Mean±SD | 1.5±1.1 | ||
| Gleason grade in TRUS-guided biopsyb, n (%) | |||
| 6 | 89 (91.8) | ||
| 7 (3+4) | 8 (8.2) |
TRUS, transrectal ultrasonography; SD, standard deviation; PSA, prostate-specific antigen; HGPIN, high-grade prostatic intraepithelial neoplasia; ASAP, atypical small acinar proliferation.
an=58, bn=97.